By API User
Licensing partners in key Asia Pacific countries have filed for approval of neffy (epinephrine nasal spray) 2 mg with regulatory agencies SAN DIEGO, Dec. 12, 2024 (GLOBE NEWSWIRE) — ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to … Continued
By API User
TEWKSBURY, MA / ACCESSWIRE / December 12, 2024 / Cambridge Isotope Laboratories, Inc. (CIL) has successfully developed and implemented a game-changing benzene-d6 recovery program, addressing major pain points for manufacturers of organic light-emitting diode (OLED) displays. This innovative service reduces costs, minimizes environmental impact, and conserves scarce deuterium supplies. OLED display producers rely heavily on … Continued
By API User
Sydney, Australia – 11 December, 2024 | NEXSEN Biotech Pty Ltd (“NEXSEN”) is setting a new standard in the diagnostic landscape with its innovative point-of-care (POC) testing solutions. Leveraging state-of-the-art nano-biotechnology, NEXSEN is addressing critical gaps in global healthcare by providing fast, accurate, and affordable diagnostic tools. StrepSure® – Innovative Solutions for Unmet Medical Needs … Continued
By API User
Sydney, Australia – 9 December, 2024 | NEXSEN Biotech Pty Ltd (“NEXSEN”), a pioneering diagnostics company, is excited to announce the launch of its pre-IPO fundraising round, targeting $2 million to $3 million. With a mission to improve global health outcomes, NEXSEN is set to deliver cutting-edge point-of-care diagnostic solutions that address critical unmet medical needs. At … Continued
By API User
Sydney, Australia, 28 November 2024 – Celosia Therapeutics, an Australian biotech company developing advanced gene therapies for neurodegenerative diseases, has completed one of the largest Series A raises for an Australian biotech start-up, raising $16.75M to advance its program for amyotrophic lateral sclerosis (ALS) disease. This landmark financing round was led by Uniseed, Australia’s … Continued
By API User
28, November, 2024 MELBOURNE, Australia — In a significant international breakthrough for the more than one billion people suffering from hypertension, Australian-supported research recently published in three of the world’s leading medical journals – The Lancet, the Journal of the American Medical Association (JAMA) and the Journal of the American College of Cardiology (JACC) – … Continued
By API User
Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programs Platform will focus on first and best-in-class drug discovery and development, demonstrating the ability to find novel insights and dramatically reduce the time and cost of discovery Recursion will host an update … Continued
By API User
BlinkLab Limited (ASX:BB1) (“BlinkLab”, “the Company”), an innovative digital healthcare company developing smartphone-based AI powered diagnostic tests for neurological conditions, is pleased to announce their participation in the landmark MAGNET (Monash Autism & ADHD Genetics and Neurodevelopment) study conducted by Monash University’s School of Psychological Sciences. Link: https://molecularautism.biomedcentral.com/articles/10.1186/s13229-021-00457-3. Highlights The MAGNET project is an ongoing … Continued
By API User
Key presentations at Eyecelerator in Chicago and AusBiotechInvest Conference PolyActiva is developing biodegradable ocular implants that provide sustained drug delivery, with its lead product targeting glaucoma, the second most common cause of irreversible blindness. Lead candidate, PA5108, met safety and efficacy endpoints in its Phase 2 clinical trial and demonstrated repeat dosing capability. Patients received … Continued
By API User
REC-3964 is Recursion’s first new chemical entity developed using the RecursionOS. REC-3964 represents a novel, non-antibiotic approach with a unique mechanism of action that binds and blocks catalytic activity of the toxin’s innate glucosyltransferase in order to inhibit the toxin produced by C. diff. in the gastrointestinal tract. There are up to 175,000 cases of … Continued
